Abstract
Objectives
To define the extent of overall brain damage in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS) and to identify non-conventional magnetic resonance (MR) metrics predictive of evolution to definite MS.
Methods
Brain conventional and magnetization transfer (MT) MRI scans were obtained from 208 CIS patients and 55 matched healthy controls, recruited in four centres. Patients were assessed clinically at the time of MRI acquisition and after a median period of 3.1 years from disease onset. The following measures were derived: T2, T1 and gadolinium (Gd)- enhancing lesion volumes (LV), normalized brain volume (NBV), MTR histogram-derived quantities of the normal-appearing white matter (NAWM) and grey matter (GM).
Results
During the follow-up, 43 % of the patients converted to definite MS. At baseline, a significant inter-centre heterogeneity was detected for T2 LV (p = 0.003), T1 LV (p = 0.006), NBV (p < 0.001) and MTR histogram-derived metrics (p < 0.001). Pooled average MTR values differed between CIS patients and controls for NAWM (p = 0.003) and GM (p = 0.01). Gdactivity and positivity of International Panel (IP) criteria for disease dissemination in space (DIS), but not NAWM and GM MTR and NBV, were associated with evolution to definite MS. The final multivariable model retained only MRI IP criteria for DIS (p = 0.05; HR = 1.66, 95 % CI = 1.00–2.77) as an independent predictor of evolution to definite MS.
Conclusions
Although irreversible tissue injury is present from the earliest clinical stages of MS, macroscopic focal lesions but not "diffuse" brain damage measured by MTR are associated to an increased risk of subsequent development of definite MS in CIS patients.
Similar content being viewed by others
References
Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M (2006) Magnetisation transfer MRI metrics predict the accumulation of disability eight years later in patients with multiple sclerosis. Brain 129:2620–2627
Allen IV, McKeown SR (1979) A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41:81–91
Anderson V, Fernando K, Davies G, Rashid W, Frost C, Fox NC, Miller DH (2007) Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroimaging 17:61–68
Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069
Barkhof F, Rocca M, Francis G, van Waesberghe JHTM, Uitfrhaag BMJ, Hommes OR, Hartung HP, Durelli L, Edan G, Fernandez O, Seeldrayers P, Soelberg Sorensen P, Margrie S, Rovaris M, Comi G, Filippi M for the ETOMS Study Group (2003) Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol 53:718–724
Beck RW, Cleary PA (1993) Optic neuritis treatment trial: one-year follow up results. Arch Ophthalmol 111:773–775
Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD (2001) Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57:1248–1252
Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158–164
Brex PA, Jenkins R, Fox NC, Crum WR, O’Riordan JI, Plant GT, Miller DH (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54:1689–1691
Brex PA, Miszkiel KA, O’Riordan JI, Plant GT, Moseley IF, Thompson AJ, Miller DH (2001) Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry 70:390–393
Caramia F, Pantano P, Di Legge S, Piattella MC, Lenzi D, Paolillo A, Nucciarelli W, Lenzi GL, Bozzao L, Pozzilli C (2002) A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. Magn Reson Imaging 20:383–388
CHAMPS Study Group (2002) MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 59:998–1005
Charil A, Yousry TA, Rovaris M, Barkhof F, De Stefano N, Fazekas F, Miller DH, Montalban X, Simon JH, Polman CH, Filippi M (2006) MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol 5:841–852
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung HP, Seeldrayers P, Soelberg Sorensen P, Rovaris M, Martinelli V, Hommes OR and the ETOMS Study Group (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357:1576–1582
Dalton CM, Brex PA, Jenkins R, Fox NC, Miszkiel KA, Crum WR, O’Riordan JI, Plant GT, Thompson AJ, Miller DH (2002) Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 73:141–147
Dalton CM, Chard DT, Davies GR, Miszkiel KA, Altmann DR, Fernando K, Plant GT, Thompson AJ, Miller DH (2004) Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 127:1101–1107
Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 47:391–395
Fernando KT, McLean MA, Chard DT, MacManus DG, Dalton CM, Miszkiel KA, Gordon RM, Plant GT, Thompson AJ, Miller DH (2004) Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 127:1361–1369
Fernando KT, Tozer DJ, Miszkiel KA, Gordon RM, Swanton JK, Dalton CM, Barker GJ, Plant GT, Thompson AJ, Miller DH (2005) Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 128:2911–2925
Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martinelli V, Grossman RI, Scotti G, Comi G, Falini A (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126:433–437
Filippi M, Horsfield MA, Morrissey SP, MacManus DG, Rudge P, McDonald WI, Miller DH (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635–641
Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G, and the ETOMS Study Group (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet 364:1489–1496
Gallo A, Rovaris M, Riva R, Ghezzi A, Benedetti B, Martinelli V, Falini A, Comi G, Filippi M (2005) Diffusion- tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 62:803–808
Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M (2000) Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 21:1034–1038
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904
Kaiser JS, Grossman RI, Polansky M, Udupa JK, Miki Y, Galetta SL (2000) Magnetization transfer histogram analysis of monosymptomatic episodes of neurologic dysfunction: preliminary findings. AJNR Am J Neuroradiol 21:1043–1047
Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67:1242–1249
Korteweg T, Tintore M, Uitdehaag B, Rovira A, Frederiksen J, Miller D, Fernando K, Filippi M, Agosta F, Rocca MA, Fazekas F, Enziger C, Matthews P, Parry A, Polman C, Montalban X, Barkhof F (2006) MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 5:221–227
Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121–127
Miller D, Barkhof F, Montalban X, Thompson AJ, Filippi M (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 4:281–288
Miller D, Barkhof F, Montalban X, Thompson AJ, Filippi M (2005) Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 4:341–348
Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry 54:683–688
Miller DH, Ormerod IE, McDonald WI, MacManus DG, Kendall BE, Kingsley DP, Moseley IF (1988) The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry 51:1569–1571
Miller DH, Ormerod IE, Rudge P, Kendall BE, Moseley IF, McDonald WI (1989) The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. Ann Neurol 26:635–639
Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116:135–146
O'Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495–503
Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389–400
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinski JS (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840–846
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 13:227–231
Rovaris M, Filippi M, Calori G, Colombo B, Campi A, Rodegher M, Comi G (1997) Intra-observer reproducibility in measuring new putative markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol 244:266–270
Rovaris M, Gass A, Bammer R, Hickman SJ, Ciccarelli O, Miller DH, Filippi M (2005) Diffusion MRI in multiple sclerosis. Neurology 65:1526–1532
Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56:407–415
Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N (2002) Accurate, robust and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17:479–489
Tintore M, Rovira A, Martinez MJ, Rio J, Diaz-Villoslada P, Brieva L, Borras C, Grive E, Capellades J, Montalban X (2000) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 21:702–706
Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, Pelayo R, Comabella M, Sastre-Garriga J, Montalban X (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67:968–972
Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, Pelayo R, Comabella M, Montalban X (2005) Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 57:210–215
Traboulsee A, Dehmeshki J, Brex PA, Dalton CM, Chard D, Barker GJ, Plant GT, Miller DH (2002) Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Neurology 59:126–128
van Waesberghe JH, Kamphorst W, DeGroot CJ, van Walderveen MA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rocca, M.A., Agosta, F., Sormani, M.P. et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 255, 683–691 (2008). https://doi.org/10.1007/s00415-008-0776-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-008-0776-z